HKEX Stock Code: 01093English|繁體|简体

2026 Interim Results

  • Revenue RMB18,594M, +40.1%
  • Reported profit attributable to shareholders of the Company RMB6,094M, +139.2%
  • Underlying profit attributable to shareholders of the Company RMB6,164M, +165.8%
  • Basic earnings per share (based on reported profit attributable to shareholders of the Company) RMB53.45 cents, +139.8%

Highlight - 2026 Interim Results

Revenue
RMB18,594M, +40.1%
Reported profit attributable to shareholders of the Company
RMB6,094M, +139.2%
Underlying profit attributable to shareholders of the Company
RMB6,164M, +165.8%
Basic earnings per share (based on reported profit attributable to shareholders of the Company)
RMB53.45 cents, +139.8%

Corporate Governance

Corporate Governance

Financial Calendar

Aug
20
Aug
20
May
28
May
27
May
27
Mar
25
Mar
25

Financial Reports

Financial Reports

Financial Summary

Financial Summary

IR Contacts

Address : Suite 3206, 32/F, Central Plaza,
18 Harbour Road, Wanchai, Hong Kong
Tel : (852) 2500 3144
Fax : (852) 2802 4552
E-mail : ir@cspc.hk
© Copyright 2026 CSPC Pharmaceutical Group Limited. All Rights Reserved.